AstraZeneca Pharmaceuticals LP is trying to stave off generic competition for Seroquel (quetiapine), its second biggest drug, for eight more months, claiming that it has exclusive rights to clinical data that FDA requires in the product labeling.
The company filed suit against FDA on March 12, contending that FDA cannot carve out this information from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?